CN1555866A - 治疗充血性心力衰竭的药物及其制备方法 - Google Patents
治疗充血性心力衰竭的药物及其制备方法 Download PDFInfo
- Publication number
- CN1555866A CN1555866A CNA2004100150058A CN200410015005A CN1555866A CN 1555866 A CN1555866 A CN 1555866A CN A2004100150058 A CNA2004100150058 A CN A2004100150058A CN 200410015005 A CN200410015005 A CN 200410015005A CN 1555866 A CN1555866 A CN 1555866A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- clear paste
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 229940079593 drug Drugs 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title claims description 19
- 206010019280 Heart failures Diseases 0.000 claims abstract description 44
- 206010007559 Cardiac failure congestive Diseases 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims description 84
- 210000000582 semen Anatomy 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 241000208340 Araliaceae Species 0.000 claims description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 25
- 235000008434 ginseng Nutrition 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 238000002481 ethanol extraction Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000011550 stock solution Substances 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 239000000463 material Substances 0.000 abstract description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 230000010354 integration Effects 0.000 description 22
- 208000011580 syndromic disease Diseases 0.000 description 19
- 230000004217 heart function Effects 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 206010030113 Oedema Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003172 expectorant agent Substances 0.000 description 8
- 230000003419 expectorant effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000037656 Respiratory Sounds Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 206010037833 rales Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000004731 jugular vein Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000004868 gas analysis Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 201000006306 Cor pulmonale Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- CTNPHHZPAJYPFO-PDXBGNJTSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-3-[(2r,4s,5r,6r)-5-[(2r,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan Chemical compound C1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C=O)CC[C@@H](C[C@@]5(O)CC[C@H]4[C@@]3(O)CC2)O[C@H]2C[C@@H]([C@@H]([C@@H](C)O2)O[C@@H]2[C@H]([C@H](O)[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](CO)O2)O)OC)=CC(=O)OC1 CTNPHHZPAJYPFO-PDXBGNJTSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- 206010013974 Dyspnoea paroxysmal nocturnal Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000035211 Heart Murmurs Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229940068811 digitalis preparation Drugs 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
分值 | 呼吸困难 | 肺部罗音 | 浮肿 | 肝大 | 颈静脉 | 胸片异常 |
1 | 轻或中度劳力型呼吸困难 | 一侧肺底罗音 | 下肢浮肿+ | 右肋下≤1.5cm | 颈静脉充盈,肝颈征+ | 肺瘀血症 |
2 | 阵发性夜间呼吸困难或重劳力性呼吸困难 | 双侧肺底罗音 | 下肢浮肿++~+++ | 右肋下1.5cm~3cm | 颈静脉零度水平3cm以上 | 间质水肿症 |
3 | 端坐呼吸或夜间咳嗽 | 罗音范围不限于双肺底 | 全身性浮肿 | 右肋下>3cm | - | 肺水肿并胸腔积液 |
4 | 休息时呼吸困难并上项表现 | - | - | - | - | - |
组别 | 例数 | 证候疗效 | ||||
显效(%) | 有效(%) | 无效(%) | 恶化(%) | 总有效(%) | ||
对照组 | 59 | 14(23.7) | 25(42.4) | 15(25.4) | 5(8.5) | 39(66.1) |
观察组 | 177 | 58(32.8) | 93(42.5) | 22(12.4) | 4(2.3) | 151(85.3)** |
组别 | 例数 | 证候总积分 | |
治疗前 | 治疗后 | ||
对照组 | 59 | 40.78±16.43 | 38.36±13.75 |
观察组 | 177 | 41.76±15.14 | 30.17±16.27△△* |
症状 | 对照组积分 | 观察组积分 | ||
治疗前 | 治疗后 | 治疗前 | 治疗后 |
心悸 | 4.50±1.62 | 4.08±1.59△ | 4.75±1.66 | 3.32±1.41△△* |
气喘 | 4.18±1.52 | 4.09±1.52 | 4.25±1.58 | 2.89±0.97△△* |
水肿 | 2.11±1.69 | 2.25±1.72 | 2.0±1.81 | 1.84±0.87△ |
乏力 | 4.57±1.26 | 4.11±1.12△ | 4.63±1.32 | 3.06±0.95△△* |
咳嗽 | 1.79±0.66 | 1.69±0.49 | 1.84±0.58 | 1.65±0.39△ |
胸痛 | 2.08±0.78 | 1.87±0.67 | 2.16±0.84 | 1.69±0.72△ |
口干 | 4.52±1.14 | 4.48±1.55 | 4.47±1.63 | 3.20±1.03△△** |
尿少 | 3.17±1.14 | 3.08±1.02 | 3.28±1.25 | 2.87±0.96△ |
形寒肢冷 | 0.85±0.12 | 0.77±0.09 | 0.89±0.15 | 0.57±0.05△ |
自汗 | 2.95±1.21 | 2.78±1.03 | 2.88±1.13 | 1.63±0.84△△* |
舌淡胖或齿印 | 0.42±0.67 | 0.38±0.55 | 0.47±0.71 | 0.26±0.43△* |
舌红 | 2.16±1.03 | 2.07±0.93 | 2.25±1.16 | 1.43±0.85△△* |
舌紫暗 | 0.78±0.52 | 0.84±0.60 | 0.82±0.57 | 0.67±0.46△ |
舌苔少或无 | 2.45±1.18 | 2.33±1.05 | 2.52±1.20 | 1.67±1.04△* |
舌苔厚腻 | 1.28±1.02 | 1.17±1.05 | 1.18±0.96 | 1.09±0.85 |
脉沉细无力 | 1.54±1.13 | 0.98±0.67△ | 1.63±1.25 | 0.56±0.73△△* |
脉沉迟无力 | 0.68±1.17 | 0.55±1.02 | 0.72±1.23 | 0.61±1.05 |
脉结代 | 0.78±1.23 | 0.69±1.16 | 0.82±1.34 | 0.60±1.03△ |
组别 | 例数 | 证候疗效 | ||||
显效(%) | 有效(%) | 无效(%) | 恶化(%) | 总有效(%) | ||
对照组 | 59 | 6(10.2) | 28(47.4) | 22(37.3) | 3(5.1) | 34(57.6) |
观察组 | 177 | 38(21.5) | 100(56.5) | 36(20.3) | 3(1.7) | 138(78.0)** |
组别 | 例数 | 心衰积分 | |
治疗前 | 治疗后 | ||
对照组 | 59 | 8.67±2.86 | 6.93±2.74△ |
观察组 | 177 | 8.84±3.51 | 5.41±2.39△△* |
指标 | 对照组(59例) | 观察组(177例) | ||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |
呼吸困难 | 2.13±0.75 | 1.67±0.85△ | 2.26±0.79 | 1.32±0.51△△* |
肺部罗音 | 1.16±0.87 | 1.08±0.74 | 1.09±0.76 | 0.79±0.87△△* |
浮肿 | 1.63±1.00 | 1.15±0.88△ | 1.61±1.02 | 1.04±0.84△△* |
肝大 | 1.24±0.75 | 1.16±0.83 | 1.28±0.72 | 0.76±0.95△△* |
颈静脉 | 1.33±0.91 | 0.72±0.77△ | 1.38±0.95 | 0.65±0.79△△* |
胸片异常 | 1.28±0.64 | 1.13±0.66 | 1.32±0.68 | 0.83±0.75△△* |
组别 | 例数 | 心功能疗效 | ||||
显效(%) | 有效(%) | 无效(%) | 恶化(%) | 总有效(%) | ||
对照组 | 59 | 8(13.5) | 29(49.2) | 19(32.2) | 3(5.1) | 37(62.7) |
观察组 | 177 | 38(21.4) | 104(58.8) | 29(16.4) | 6(3.4) | 140(80.2)* |
对照组(59例) | 治疗组(177例) | |||||||||||||||
治疗前 | 治疗后 | 治疗前 | 治疗后 | |||||||||||||
心功能 | I | II | III | IV | I | II | III | IV | I | II | III | IV | I | II | III | IV |
例数 | 0 | 19 | 31 | 9 | 16 | 24 | 13 | 6 | 0 | 54 | 83 | 40 | 62 | 85 | 23 | 7 |
百分比(%) | 0 | 32.2 | 50.5 | 15.2 | 27.1△ | 40.7 | 22.4△ | 10.2 | 0 | 30.5 | 46.9 | 22.6 | 35△* | 48△ | 13△* | 4△ * |
指标 | 治疗前 | 治疗后 | ||
对照组 | 观察组 | 对照组 | 观察组 | |
全血比粘度 | 12.96±4.59 | 13.76±3.41 | 13.81±4.11 | 10.13±5.03△* |
血浆比粘度 | 1.71±0.18 | 1.67±0.15 | 1.63±0.22 | 1.46±0.18△△** |
还原血粘度 | 19.68±6.23 | 21.55±4.66 | 21.38±5.74 | 18.55±4.73△* |
RBC压积 | 0.46±0.12 | 0.45±0.12 | 0.47±0.11 | 0.38±0.08△△* |
血沉 | 48.60±5.30 | 41.10±4.90△ | 51.20±6.50 | 36.70±4.60△△* |
RBC聚集指数 | 27.2±13.50 | 26.1±12.16 | 29.81±6.11 | 21.97±4.61△△* |
血沉方程K值 | 118.9±39.0 | 120.0±32.3 | 125.1±32.3 | 96.7±29.7△△** |
纤维蛋白原 | 4.34±1.66 | 4.15±1.42 | 4.45±1.55 | 3.74±1.57△ |
RBC硬化指数 | 5.84±1.29 | 5.67±1.14 | 5.92±1.26 | 5.72±1.19 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100150058A CN1308023C (zh) | 2004-01-05 | 2004-01-05 | 治疗充血性心力衰竭的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100150058A CN1308023C (zh) | 2004-01-05 | 2004-01-05 | 治疗充血性心力衰竭的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1555866A true CN1555866A (zh) | 2004-12-22 |
CN1308023C CN1308023C (zh) | 2007-04-04 |
Family
ID=34351268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100150058A Expired - Lifetime CN1308023C (zh) | 2004-01-05 | 2004-01-05 | 治疗充血性心力衰竭的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1308023C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1981803B (zh) * | 2005-12-13 | 2011-10-12 | 黄伟民 | 一种防治心血管疾病的中药组合物及其制备方法 |
CN104547175A (zh) * | 2015-01-15 | 2015-04-29 | 何丹 | 一种治疗风湿性心脏病的中药 |
CN111035714A (zh) * | 2018-10-15 | 2020-04-21 | 广州白云山中一药业有限公司 | 中药组合物在制备抗血栓药物中的应用 |
-
2004
- 2004-01-05 CN CNB2004100150058A patent/CN1308023C/zh not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1981803B (zh) * | 2005-12-13 | 2011-10-12 | 黄伟民 | 一种防治心血管疾病的中药组合物及其制备方法 |
CN104547175A (zh) * | 2015-01-15 | 2015-04-29 | 何丹 | 一种治疗风湿性心脏病的中药 |
CN111035714A (zh) * | 2018-10-15 | 2020-04-21 | 广州白云山中一药业有限公司 | 中药组合物在制备抗血栓药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1308023C (zh) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1813868A (zh) | 一种治疗和改善慢性疲劳综合症的组合物及其制备方法 | |
CN101062377A (zh) | 一种通经活络、祛风散寒、消炎止痛的膏药及其制备方法 | |
CN1565552A (zh) | 治疗免疫功能低下或紊乱的中药 | |
CN1245189C (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1308023C (zh) | 治疗充血性心力衰竭的药物及其制备方法 | |
CN1583138A (zh) | 益气养心安神的中药组合物及其制备方法和鉴别方法 | |
CN100335074C (zh) | 一种治疗中风病的中药口服液 | |
CN1686485A (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1211094C (zh) | 一种治疗肺结核病的药物 | |
CN1290529C (zh) | 治疗痛风、高尿酸血症和高脂血症的药物及其制备方法 | |
CN1240412C (zh) | 一种治疗痔疮的中药复方制剂及其制备方法 | |
CN1256143C (zh) | 抗病毒的中药复方制剂 | |
CN1820770A (zh) | 一种治疗中风的中药组合物及其制备方法 | |
CN1211111C (zh) | 一种降血脂中药 | |
CN1310002A (zh) | 中西医治疗支气管哮喘的药物 | |
CN101062374A (zh) | 一种治疗癌症的中药组合物胶囊的制备方法及其产品 | |
CN1284589C (zh) | 一种治疗急性脑血管疾病的药物及其制备方法 | |
CN1650903A (zh) | 从天然植物中药有效成分中提取清音利嗓制品药物的方法 | |
CN1247250C (zh) | 一种预防和治疗氟、铅、汞、砷中毒的药物及其生产方法 | |
CN1162177C (zh) | 一种治疗脂肪肝的药物 | |
CN1923211A (zh) | 一种黄芪甲苷注射液及其制备方法 | |
CN1222305C (zh) | 治疗肝肾不足、气阴亏虚的中药及其制备方法 | |
CN1233361C (zh) | 一种治疗心血管疾病的中药组合物 | |
CN1562114A (zh) | 一种治疗慢性前列腺炎的药物及其制备方法 | |
CN1745781A (zh) | 一种治疗肛肠疾病的外用中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU BAIYUNSHAN ZHONGYI PHARMACEUTICAL CO., L Free format text: FORMER NAME: GUANGZHOU ZHONGYI PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: 510530, No. 32, Po pan Road, Guangzhou, Guangdong, Luogang District Patentee after: GUANGZHOU BAIYUNSHAN ZHONGYI PHARMACEUTICAL Co.,Ltd. Address before: 11, building 510620, west block, Times Square, 28 Tianhe North Road, Guangzhou, Guangdong Patentee before: GUANGZHOU ZHONGYI PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070404 |
|
CX01 | Expiry of patent term |